Product Details
| Product Name:
SSE15206 |
CAS No.:
1370046-40-4 |
| Purity:
98.81% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | SSE15206 |
| Description | SSE15206 is a microtubule polymerization inhibitor that overcomes multidrug resistance, causing aberrant mitosis and resulting in G2/M arrest due to incomplete spindle formation in cancer cells. |
| Cell Research | Fluorescence intensity of tubulin (4?μM) in the presence of colchicine (20?μM) and SSE15206 at indicated concentrations was measured. DMSO was used as a solvent control while 50?μM nocodazole was used as a positive control for colchicine displacement. Samples were incubated for 60?min at 37℃before measurement of fluorescence (excitation at 355?nm and emission at 460?nm). KB-V1 and A2780-Pac-Res cells were incubated with 5?μM rhodamine, for 1?hour at 37℃in the presence or absence of inhibitors. Cells were then washed twice with PBS and incubated in the efflux medium (their respective growth media) in the presence of DMSO, 20?μM verapamil, and 10?μM SSE15206 for 3?hours. The percentage of rhodamine 123 positive cells was determined . Experiments were done in duplicates with 4–5 readings for each sample in each experiment. |
| In vitro | Treatment of cells with SSE15206 causes aberrant mitosis resulting in G2/M arrest due to incomplete spindle formation, a phenotype often associated with drugs that interfere with microtubule dynamics. SSE15206 is able to overcome resistance to chemotherapeutic drugs in different cancer cell lines including multidrug-resistant KB-V1 and A2780-Pac-Res cell lines overexpressing MDR-1, making it a promising hit for the lead optimization studies to target multidrug resistance. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 150 mg/mL (403.82 mM)
|
| Keywords | Inhibitor | SSE 15206 | SSE15206 | Apoptosis | Microtubule/Tubulin | inhibit | SSE-15206 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:57089-60-8
$195.00 / 1mg
-
CAS:900510-03-4
$30.00 / 5mg
-
CAS:61-90-5
$42.00 / 100mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States